JP2020533948A - 抗ｔｒｅｍ２抗体及びその使用方法 - Google Patents

抗ｔｒｅｍ２抗体及びその使用方法 Download PDF

Info

Publication number
JP2020533948A
JP2020533948A JP2019559017A JP2019559017A JP2020533948A JP 2020533948 A JP2020533948 A JP 2020533948A JP 2019559017 A JP2019559017 A JP 2019559017A JP 2019559017 A JP2019559017 A JP 2019559017A JP 2020533948 A JP2020533948 A JP 2020533948A
Authority
JP
Japan
Prior art keywords
al2p
amino acid
seq
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019559017A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533948A5 (enExample
Inventor
ティナ シュワーブ，
ティナ シュワーブ，
エリック ブラウン，
エリック ブラウン，
フィリップ コング，
フィリップ コング，
イラーリア タッシ，
イラーリア タッシ，
スンジュ リー，
スンジュ リー，
アーノン ローゼンタール，
アーノン ローゼンタール，
ロバート ペジャール，
ロバート ペジャール，
ネルズ ピー． ニールソン，
ネルズ ピー． ニールソン，
Original Assignee
アレクトル エルエルシー
アレクトル エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクトル エルエルシー, アレクトル エルエルシー filed Critical アレクトル エルエルシー
Publication of JP2020533948A publication Critical patent/JP2020533948A/ja
Publication of JP2020533948A5 publication Critical patent/JP2020533948A5/ja
Priority to JP2022186859A priority Critical patent/JP7554247B2/ja
Priority to JP2024091312A priority patent/JP2024147536A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019559017A 2017-08-03 2018-08-02 抗ｔｒｅｍ２抗体及びその使用方法 Pending JP2020533948A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022186859A JP7554247B2 (ja) 2017-08-03 2022-11-22 抗ｔｒｅｍ２抗体及びその使用方法
JP2024091312A JP2024147536A (ja) 2017-08-03 2024-06-05 抗ｔｒｅｍ２抗体及びその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762541019P 2017-08-03 2017-08-03
US62/541,019 2017-08-03
US201862636095P 2018-02-27 2018-02-27
US62/636,095 2018-02-27
PCT/US2018/045068 WO2019028292A1 (en) 2017-08-03 2018-08-02 ANTI-TREM2 ANTIBODIES AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022186859A Division JP7554247B2 (ja) 2017-08-03 2022-11-22 抗ｔｒｅｍ２抗体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2020533948A true JP2020533948A (ja) 2020-11-26
JP2020533948A5 JP2020533948A5 (enExample) 2021-09-09

Family

ID=63364160

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019559017A Pending JP2020533948A (ja) 2017-08-03 2018-08-02 抗ｔｒｅｍ２抗体及びその使用方法
JP2022186859A Active JP7554247B2 (ja) 2017-08-03 2022-11-22 抗ｔｒｅｍ２抗体及びその使用方法
JP2024091312A Pending JP2024147536A (ja) 2017-08-03 2024-06-05 抗ｔｒｅｍ２抗体及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022186859A Active JP7554247B2 (ja) 2017-08-03 2022-11-22 抗ｔｒｅｍ２抗体及びその使用方法
JP2024091312A Pending JP2024147536A (ja) 2017-08-03 2024-06-05 抗ｔｒｅｍ２抗体及びその使用方法

Country Status (34)

Country Link
US (3) US10676525B2 (enExample)
EP (2) EP3601358B1 (enExample)
JP (3) JP2020533948A (enExample)
KR (2) KR20250026882A (enExample)
CN (3) CN119192376A (enExample)
AU (1) AU2018311055B2 (enExample)
BR (1) BR112019022752A2 (enExample)
CA (1) CA3061755A1 (enExample)
CL (2) CL2019003093A1 (enExample)
CO (1) CO2019012210A2 (enExample)
CR (3) CR20230169A (enExample)
DK (1) DK3601358T5 (enExample)
EC (1) ECSP19078429A (enExample)
ES (1) ES2952982T3 (enExample)
FI (1) FI3601358T3 (enExample)
HR (1) HRP20230675T1 (enExample)
HU (1) HUE062436T2 (enExample)
IL (2) IL315241A (enExample)
LT (1) LT3601358T (enExample)
MD (1) MD3601358T2 (enExample)
MX (2) MX2019012868A (enExample)
MY (1) MY201526A (enExample)
NZ (1) NZ758301A (enExample)
PE (1) PE20200148A1 (enExample)
PH (1) PH12019502459A1 (enExample)
PL (1) PL3601358T3 (enExample)
PT (1) PT3601358T (enExample)
RS (1) RS64419B1 (enExample)
SI (1) SI3601358T1 (enExample)
SM (1) SMT202300281T1 (enExample)
TW (3) TWI868807B (enExample)
UA (1) UA129513C2 (enExample)
WO (1) WO2019028292A1 (enExample)
ZA (2) ZA201906730B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR102506663B1 (ko) 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
KR102878840B1 (ko) 2019-11-22 2025-10-31 일라이 릴리 앤드 캄파니 Trem2 항체 및 그의 용도
EP3986937A1 (en) * 2019-12-05 2022-04-27 Alector LLC Methods of use of anti-trem2 antibodies
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP7745557B2 (ja) * 2020-02-24 2025-09-29 アレクトル エルエルシー 抗ｔｒｅｍ２抗体の使用方法
MX2022012182A (es) * 2020-04-03 2022-12-08 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
WO2023114499A1 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025166058A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
CN118420764A (zh) * 2024-04-02 2024-08-02 上海宏成药业有限公司 抗trem2抗体及其用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049641A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
DK187280A (da) 1980-04-30 1981-10-31 Novo Industri As Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
ATE149570T1 (de) 1992-08-17 1997-03-15 Genentech Inc Bispezifische immunoadhesine
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997011971A1 (en) 1995-09-28 1997-04-03 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
US6849425B1 (en) * 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
CA2489145A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Insulin-sensitizing agent
JP2004073182A (ja) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
JP2006515747A (ja) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
EP1587834B1 (en) 2002-12-23 2011-07-06 Schering Corporation Uses of il-23 mammalian cytokine; related reagents
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
MX2007008017A (es) 2004-12-31 2007-09-12 Genentech Inc Polipeptidos que se ligan a br3 y usos de los mismos.
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA3022097C (en) 2006-03-15 2020-10-27 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
WO2008042261A2 (en) * 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2121750A2 (en) * 2007-01-16 2009-11-25 Wyeth Inflammation treatment, detection and monitoring via trem-1
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3753947A1 (en) 2007-09-14 2020-12-23 Adimab, LLC Rationally designed, synthetic antibody libraries and uses therefor
EP2195344A4 (en) 2007-10-05 2011-07-06 Univ Maryland NEW COMPOSITIONS AND METHODS FOR STIMULATING ERYTHROPOIESE IN A MAMMALIAN
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
JP6184695B2 (ja) 2009-12-04 2017-08-23 ジェネンテック， インコーポレイテッド 多重特異性抗体、抗体アナログ、組成物、及び方法
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
JP6266343B2 (ja) 2010-07-16 2018-01-24 アディマブ， エルエルシー 抗体ライブラリー
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
TWI559929B (en) * 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
JP2018516901A (ja) 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーＳｙｎａｐｔｅｃ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｌｃ アミロイドβのガランタミンクリアランス
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
KR102415925B1 (ko) * 2016-01-11 2022-07-04 삼성디스플레이 주식회사 표시장치
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
AU2018307877A1 (en) 2017-07-27 2020-01-02 Novartis Ag Sheddase resistant TREM2 variants
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
PE20200486A1 (es) 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos
CA3075285A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
JP2021513969A (ja) 2018-02-14 2021-06-03 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ Ｔｒｅｍまたはｔｒｅｍｌタンパク質を調節するための組成物および使用方法
MX2022012182A (es) * 2020-04-03 2022-12-08 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4337317A1 (en) * 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049641A1 (en) * 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016064895A1 (en) * 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP4248996A2 (en) 2023-09-27
MX2024001803A (es) 2024-03-06
DK3601358T5 (da) 2024-09-02
TW202342547A (zh) 2023-11-01
TWI868807B (zh) 2025-01-01
CN110621696A (zh) 2019-12-27
TWI811229B (zh) 2023-08-11
EP4248996A3 (en) 2023-11-08
MD3601358T2 (ro) 2023-10-31
EP3601358B1 (en) 2023-05-17
IL270235A (enExample) 2019-12-31
TW202511296A (zh) 2025-03-16
CR20230170A (es) 2023-05-31
TW201912654A (zh) 2019-04-01
ECSP19078429A (es) 2020-02-28
SMT202300281T1 (it) 2023-11-13
CL2019003093A1 (es) 2020-03-20
FI3601358T3 (fi) 2023-07-20
CN110621696B (zh) 2024-10-25
CL2020001974A1 (es) 2020-10-23
JP7554247B2 (ja) 2024-09-19
SI3601358T1 (sl) 2023-10-30
US20190040130A1 (en) 2019-02-07
ES2952982T3 (es) 2023-11-07
PL3601358T3 (pl) 2023-10-02
AU2018311055A1 (en) 2019-11-14
KR20200033794A (ko) 2020-03-30
MY201526A (en) 2024-02-27
JP2023029882A (ja) 2023-03-07
US20230312712A1 (en) 2023-10-05
JP2024147536A (ja) 2024-10-16
MX2019012868A (es) 2019-11-28
ZA202211057B (en) 2024-02-28
CR20230169A (es) 2023-05-31
WO2019028292A1 (en) 2019-02-07
PT3601358T (pt) 2023-08-30
ZA201906730B (en) 2023-04-26
AU2018311055B2 (en) 2025-05-29
KR102769231B1 (ko) 2025-02-20
CO2019012210A2 (es) 2020-04-01
KR20250026882A (ko) 2025-02-25
CN119192377A (zh) 2024-12-27
CR20190485A (es) 2020-02-10
CA3061755A1 (en) 2019-02-07
HUE062436T2 (hu) 2023-11-28
CN119192376A (zh) 2024-12-27
US11634489B2 (en) 2023-04-25
US10676525B2 (en) 2020-06-09
PE20200148A1 (es) 2020-01-17
RS64419B1 (sr) 2023-09-29
IL315241A (en) 2024-10-01
UA129513C2 (uk) 2025-05-21
NZ758301A (en) 2023-07-28
BR112019022752A2 (pt) 2020-05-19
IL270235B2 (en) 2025-02-01
HRP20230675T1 (hr) 2023-09-29
PH12019502459A1 (en) 2020-07-20
DK3601358T3 (da) 2023-07-31
US20200317776A1 (en) 2020-10-08
LT3601358T (lt) 2023-08-10
IL270235B1 (en) 2024-10-01
EP3601358A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
JP7554247B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP7060502B2 (ja) 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
JP2022028653A (ja) 抗Ｓｉｇｌｅｃ－７抗体及びその使用方法
JP2020532947A (ja) 抗ｃｄ３３抗体及びその使用方法
JP2021534797A (ja) 抗ｃｄ３３抗体及びその使用方法
JP2021531027A (ja) 抗Ｓｉｇｌｅｃ−５抗体及びその使用方法
CN112512638B (zh) 抗siglec-7抗体及其使用方法
JP2023506014A (ja) 抗ｃｄ３３抗体の使用方法
HK40101643A (en) Anti-trem2 antibodies and methods of use thereof
EA044134B1 (ru) Анти-trem2 антитела и способы их применения
HK40019817B (en) Anti-trem2 antibodies and methods of use thereof
HK40019817A (en) Anti-trem2 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314